NANJING, China, May 21, 2024
/PRNewswire/ -- The 10th European Stroke Organization Congress
(ESOC), held in Basel, Switzerland
from May 15 to 17, 2024, showcased
six studies on Sanbexin® (Edaravone and Dexborneol Concentrated
Solution for Injection) and a new dosage form of sublingual tablets
under development. These presentations brought new medical evidence
on the mechanism of action and clinical application of Sanbexin® in
treating stroke.
Highlights
Sanbexin®, the only Class 1 innovative drug approved worldwide
since 2015, has been shown to reduce brain cell damage and
dysfunction caused by ischemia and hypoxia in stroke patients. Its
significance lies in its ability to combat the devastating effects
of stroke, which is the second most common fatal disease globally
and the first most common in China.
The high recurrence rate, disability rate, and mortality rate
associated with stroke place a heavy burden on society. In
China, the incidence rate of
ischemic stroke is the highest worldwide. Sanbexin® has been
approved to address these challenges, offering new hope for
patients and their families.
Furthermore, the New Drug Application (NDA) for Sublingual
Tablets of Sanbexin® has been accepted by the National Medical
Products Administration (NMPA) on June 28,
2023. This development is expected to fill a critical gap in
first-time and out-of-hospital drug delivery after stroke onset,
increasing accessibility to the entire treatment course from
hospital-based care to out-of-hospital care for patients.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/simcere-phar-maceuticals-presented-six-studies-on-sanbexin-at-esoc-2024-302151088.html
SOURCE Simcere